A Phase 1, Open-Label, Single Dose Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant [0.03%]
一项评估利培酮植入剂在稳定的精神分裂症患者中单次给药的I期、开放性药代动力学研究
Ryan Dammerman,Sonnie Kim,Mathews Adera et al.
Ryan Dammerman et al.
A Phase-1, 6-Month Open-Label, Dose-Ranging Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant [0.03%]
一项针对稳定服用利培酮植入剂的精神分裂症患者的I期、为期6个月的开放标签剂量范围药代动力学研究
Ryan Dammerman,Sonnie Kim,Mathews Adera et al.
Ryan Dammerman et al.
Unmet Medication Coverage Needs among Adults with Attention Deficit/Hyperactivity Disorder (ADHD) [0.03%]
注意缺陷多动障碍成人患者未获满足的药物保障需求
Thomas E Brown,Emuella Flood,Phillip Sarocco et al.
Thomas E Brown et al.
Persisting Psychosocial Impairments in Adults Being Treated with Medication for Attention Deficit/Hyperactivity Disorder [0.03%]
注意缺陷多动障碍药物治疗成人患者的持续性心理社会功能缺损
Thomas E Brown,Emuella Flood,Phillip Sarocco et al.
Thomas E Brown et al.
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder [0.03%]
Valbenazine(NBI-98854)治疗迟发性运动障碍及精神分裂症或分裂情感障碍患者的疗效研究
John M Kane,Christoph U Correll,Grace S Liang et al.
John M Kane et al.
Background: Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia (TD). The KINECT 3 study (NCT02274558) evaluated the effects of VBZ ...
Randomized Controlled Trial
Psychopharmacology bulletin. 2017 Aug 1;47(3):69-76. DOI: 2017
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder [0.03%]
治疗精神分裂症或心境障碍伴迟发性运动障碍患者长期使用valbenazine(NBI-98854)的安全性和耐受性
Richard C Josiassen,John M Kane,Grace S Liang et al.
Richard C Josiassen et al.
Background: The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind, placebo-controlled (DBPC) trials in adults with tardive dyskinesia (TD) who had a diagnosis of sc...
Randomized Controlled Trial
Psychopharmacology bulletin. 2017 Aug 1;47(3):61-68. DOI: 2017
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder [0.03%]
valbenazine治疗心境障碍伴迟发性运动障碍患者的疗效
Christoph U Correll,Richard C Josiassen,Grace S Liang et al.
Christoph U Correll et al.
Background: Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia (TD). The KINECT 3 study (NCT02274558) evaluated the effects of VBZ ...
Randomized Controlled Trial
Psychopharmacology bulletin. 2017 Aug 1;47(3):53-60. DOI: 2017
Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects [0.03%]
健康男性受试者单次给药及每日一次多次给药条件下valbenazine的安全性、耐受性和药代动力学研究
Rosa Luo,Haig Bozigian,Roland Jimenez et al.
Rosa Luo et al.
Valbenazine (VBZ) is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia. The safety, tolerability and pharmacokinetics of VBZ following single and repeat once-daily (QD) dosing were evalua...
Randomized Controlled Trial
Psychopharmacology bulletin. 2017 Aug 1;47(3):44-52. DOI: 2017
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil [0.03%]
利培酮酯在门诊患者中治疗精神分裂症一年过程中的代谢和内分泌特征
Henry A Nasrallah,Ralph Aquila,Arielle D Stanford et al.
Henry A Nasrallah et al.
Background: We assessed long-term metabolic and endocrine profiles of outpatients with schizophrenia participating in a one-year open-label extension study of monthly aripiprazole lauroxil (AL), a long-acting injectable a...
Clinical Trial
Psychopharmacology bulletin. 2017 Aug 1;47(3):35-43. DOI: 2017